Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease

Summary

The purpose of this study is to evaluate the safety and efficacy of three target doses of melperone compared to placebo in the treatment of psychosis associated with Parkinson's disease. Subjects will be enrolled at approximately 20 investigational sites in the United States (U.S.) and 15 Ex-US sites. The maximum study duration will be 10 weeks. Subjects will have the option of continuing in an open-label extension study.

Timeline

Start

2005-07

Primary completion

2008-03

Completion

2008-04

Outcome

Missed primary endpoint

registry Melperone HCl - 40 mg vs Placebo; p = 0.1519; Difference of LS mean -2.9 (95% CI -8.5 to 2.7); ANCOVA NCT00125138 ↗

Drugs

Indications